Teleflex Completes Acquisition of BIOTRONIK's Vascular Unit
Deal News | Jul 01, 2025 | Globenewswire
Teleflex Incorporated, a global leader in medical technology, has finalized its acquisition of BIOTRONIK's Vascular Intervention business, initially announced in February 2025. The acquisition, valued at $760 million, brings an expanded array of therapeutic products into Teleflex's offerings, enhancing their position in the competitive percutaneous coronary intervention market. The strategic purchase aims to bolster Teleflex's presence in coronary and peripheral interventions globally, with high expectations for increased market share and innovative developments, including plans for a U.S. pivotal study for the Freesolve sirolimus-eluting Resorbable Metallic Scaffold (RMS). Following the successful acquisition, Teleflex forecasts significant revenue increases from the newly acquired business, anticipated to generate $177 million in revenue in the latter half of 2025 and contribute growth in future earnings per share.
Sectors
- Medical Technology
- Healthcare Equipment & Services
Geography
- United States – Teleflex is headquartered in Wayne, Pennsylvania, and the announcement and strategic operations are centered in the U.S.
- Germany – BIOTRONIK, the company whose Vascular Intervention business has been acquired, is based in Germany.
Industry
- Medical Technology – Teleflex and BIOTRONIK operate within the medical technology sector, particularly focusing on the development and distribution of cardiovascular intervention products.
- Healthcare Equipment & Services – The acquisition concerns the healthcare sector as it involves the acquisition of therapeutic products and services related to vascular interventions.
Financials
- $760 million – The cash payment made by Teleflex for the acquisition of BIOTRONIK's Vascular Intervention business.
- $177 million – The expected revenue from acquired products in the second half of 2025.
- $0.10 – The expected accretion to Teleflex's adjusted earnings per share in the first year post-acquisition.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Teleflex Incorporated | Acquirer | Company | A global provider of medical technologies aiming to expand its product offerings and market presence through strategic acquisitions. |
| BIOTRONIK SE & Co. KG | Target | Company | A Germany-based company known for its innovations in cardiovascular medical devices. |
| Liam Kelly | Chairman, President and CEO | Person | He provided official statements regarding the completion and strategic significance of the acquisition for Teleflex. |